IMPORTANT: All email correspondence related to abstract submission and notification processes will be sent from alz@confex.com . Add this address to your safe sender list or address book to ensure you receive all communications. An email will be sent to the submitter as you complete step 1 of the submission process and when your submission is complete. Invitation emails are sent to the presenting author only. It is your responsibility to contact the Alzheimer's Association if you do not receive email correspondence generated through the abstract system (contact abstracts@alz.org if you are not receiving emails).

<< >> Individual Oral and Poster submissions:

(See below for Featured Research Sessions) Choose your "Presentation Preference" (poster or oral) Choose the Theme, Topic, and Subtopic View AAIC Themes, Topics and Subtopics View AIC Themes View Technology and Dementia Themes Abstract Title Abstract Description

The following headers are required: Background

Methods

Results

Conclusions All four sections combined cannot exceed 350 words. Verify the word count prior to entry. Note the one exception: submissions for the "Dementia Care Practice" topic require a 350 word or less "proposal/project description."



References must be included in the abstract body. Files submitted during submission listing references will not appear in the published version of the abstract. Files for Tables and Figures cannot be uploaded in the body of the abstract but can be added as a separate file(s). Acceptable formats: .jpeg, .gif, or .png) If you plan to upload tables or figures to supplement your abstract, save them in advance as JPG, PNG, or GIF files.

Save one figure, chart or table per file. Do not add multiple images to one file or they may not appear in the published version of the abstract.

Up to 6 files may be uploaded.

Word, Excel, and PDF files are not accepted.

Text only files will be excluded from the published version of the abstract. Learning Objective(s) (One required, max of three) Keyword selection (One required; max of three. A list of acceptable keywords will be available at the time of submission) Author Information (collect the information below in advance) PRESENTING AUTHOR: Full Name

E-mail Address

Institution/Organization

City, State/Province, Country, Zip/Postal Code

Phone Number

Curriculum Vitae (Acceptable formats: .pdf, .doc, or .docx file) CO-AUTHOR(S): (if applicable; submitter is required to submit this information) Full Name

Degree(s)

Institution/Organization

E-mail Address

City, State/Province, Country AAIC Featured Research Session Proposals (FRS): Featured Research Sessions (FRS) (offered only as part of the AAIC program) provide an opportunity for researchers to submit an entire session organized around a topic. [NOTE] A session organizer is responsible for identifying, confirming and entering the session participants, initiating the session submission, entering overview information, and communicating with the speakers to ensure they individually enter their abstract details by the deadline. As the session submitter initiates the proposal, each speaker will receive an email with a direct link to complete their abstract submission.



A session organizer is responsible for identifying, confirming and entering the session participants, initiating the session submission, entering overview information, and communicating with the speakers to ensure they individually enter their abstract details by the deadline. As the session submitter initiates the proposal, each speaker will receive an email with a direct link to complete their abstract submission. Click here to download the 2017 FRS Helpful Guide (step-by-step). Is there a process to ensure my abstract is considered for an oral presentation if it is not accepted as part of a Featured Research Session (FRS) proposal? Yes, we have a solution for this case. Researchers submitting an abstract as part of a FRS may also submit the same abstract for oral presentation consideration. If interested, it is the responsibility of the submitter to also submit the abstract via the submission option of "AAIC: Individual Abstract (Oral or Poster)." Important: if the abstract is accepted as part of a FRS, the FRS will take precedence and the individual abstract cannot be presented in an oral session. Of note, non-accepted FRS abstracts that receive an appropriate average review score will automatically be considered for an optional poster presentation (there is no need to submit the abstract twice in this case). Will an abstract submitted as part of a Featured Research Session (FRS) be considered for a poster presentation if the FRS is not selected? Yes, non-accepted FRS abstracts that receive an appropriate average review score will automatically be considered for an optional poster presentation (there is no need to submit the abstract twice in this case). Of note, non-selected FRS abstracts will not be considered for an oral presentation unless the abstract is submitted twice via the appropriate submission process (see the FAQ, "Is there a process to ensure my abstract is considered for an oral presentation if it is not accepted as part of a Featured Research Session (FRS) proposal?"). Step 1: SESSION SUBMITTERS Your list of what to prepare and gather prior to initiating your session proposal includes the following: SESSION CHAIR(S): Identify and confirm the participation of 1-2 session chairs (minimum 1, maximum 2). Note: An individual may be both a session chair and a speaker.

Enter the following for each chair: Full Name, E-mail Address, Institution/Organization, City, State/Province, Country, Zip/Postal Code, Phone SESSION SPEAKERS: Identify and confirm a total of four speakers Reminder: Only a select number of proposals will be invited to present at AAIC; please inform your session speakers that a determination will be made by the Scientific Program Committee by March 27 .

Enter the following for each speaker: Abstract title, Full Name, E-mail Address, Title, Degree(s), Institution/Organization, City, State/Province, Country, Phone Number ENTRY OF SESSION OVERVIEW INFORMATION: Selection of the session Theme, Topic and Subtopic

Session Title

Session Overview ( up to 250 words; descriptive overview )

) Affirmations Checklist

PowerPoint and Recording Permissions

Learning Objectives and Keyword Selection As the organizer/submitter enters each speaker's name, email and presentation title, an email will be generated to the speaker . The email will include a direct link to complete their abstract submission. Step 2: SESSION SPEAKERS Upon receipt of the emails, individual speakers must enter: Abstract (up to 350 words; must include background, methods, results, conclusions)

Supplemental images (if applicable): Save any tables, charts, figures in advance as JPG, PNG, or GIF files

Curriculum Vitae (acceptable formats: .pdf, .doc, or .docx file)

Disclosures

Abstract Co-authors (if applicable): Full Name, degree(s), institution/organization, email address, and phone number Step 3: SESSION SUBMITTER It is the session submitter's responsibility to ensure that your four session speakers fully entered their abstract details by the deadline. Check the status of your session: As the submitter, you received a "session initiated" email generated by the system (from alz@confex.com; check your spam folder; the email includes your log-in details). Once in the session, click on Step 2 from the Control Panel (left side of the screen). Within the presentation table, the "status" column for all four presentations must be marked "Complete." Embargo Policy

<< >> AAIC Embargo Policy The Alzheimer's Association International Conference® (AAIC®) is a well-recognized, global platform for news regarding advances in Alzheimer's and dementia research. If you are interested in having the research you present at AAIC eligible for inclusion in AAIC news releases and news conferences, it must not be published (online or hard copy) or presented, in whole or in part, in any manner, previous to presentation at AAIC. (Note: The Association reserves the right to also include previously published material in its news program, if it so chooses, but this is generally not the case.) All materials submitted to AAIC are embargoed for publication and broadcast until the officially scheduled date and time of presentation at AAIC, unless the Alzheimer's Association provides written notice of change of date and/or time in advance, such as on an AAIC news release. If there are questions, please contact the Alzheimer's Association Public Relations Department at media@alz.org. The news embargo for abstracts and scientific presentations included in the AAIC news program will be listed on the news release that includes that abstract/presentation. This is regardless of the actual time of presentation at AAIC.

News embargoes for plenaries and oral sessions not included in the AAIC news program are at the beginning of each individual talk (not the overall session). For example, for an oral presentation session starting at 2:00 pm where each talk is 15 minutes, the news embargo on the: 1st talk = 2:00 pm 2nd talk = 2:15 pm 3rd talk = 2:30 pm

The news embargo on a poster session is at the scheduled beginning of the session. Public and news announcements made in advance of AAIC that a scientist or company is scheduled to make a presentation at AAIC may include the date, time, location and topic of presentation, but may not include the methods, results and/or conclusions, nor the type or direction of results, even if that is included in the name/title of the submitted abstract. For that reason, authors are discouraged from putting the type and/or direction of results in the abstract title. All news media representatives, scientists and their funders, and exhibitors/sponsors agree to honor the news embargoes and release times stated on news releases and other news materials issued by the Alzheimer's Association/AAIC. If a reporter or news media outlet breaks an AAIC news embargo, the Alzheimer's Association reserves the right to revoke their press access and credentials for the current event and future Alzheimer's Association conferences and events. If a scientist or company that is a participant in an AAIC news briefing or news release is discovered to have broken the news embargo, or encouraged the breaking of a news embargo, the Alzheimer's Association reserves the right to remove the participant from the news briefing and remove that scientist's/company's information from the news release. In addition, consequences for violation of the news embargo may include retraction of the accepted abstract from AAIC and/or loss of privileges of presenting research at AAIC in the future. SEC-Related Issues If a publicly traded company is advised that it is legally required to disclose certain data or other information from a confidential AAIC abstract in advance of the AAIC news embargo to satisfy requirements of the U.S. Securities and Exchange Commission or a corresponding regulatory body in a country where the company's stock is traded (collectively, "SEC"), that company must submit to AAIC, in advance of the SEC-required disclosure: Written notification of the time, manner and recipients of the company's release; and

A letter signed by the company's legal counsel, advising that (a) public disclosure of the information is necessary for the company to comply with applicable securities laws, and (b) the information disclosed is the minimum necessary for such compliance. If this is done, the abstract will not be automatically rejected or removed from AAIC on the basis of the SEC-required release of data or other information, though the situation is still subject to AAIC review. At a minimum, AAIC may in its discretion change the position of the abstract in AAIC, e.g., from oral presentation to poster. The abstract will most likely be ineligible for the AAIC news program. The company may issue a news release at the time of SEC-required disclosure. The AAIC abstract itself may not be released publicly by the company or lead author. Mention may be made that full details will be presented at AAIC. AAIC would prefer that the news release: Summarize study data cited in the abstract in a qualitative rather than quantitative manner.

Avoid interpretations about the implications of the data for practice. As an example, a statement that a study "met its primary endpoint of improving cognition" is qualitative, while "ADAS-Cog scores remained stable for 18 months in the treated group" would be considered quantitative. A quote such as "We are encouraged by these promising results" would not be viewed as interpretive, while a quote such as "These findings support [drug] as first line therapy in mild to moderate Alzheimer's" would be seen as an interpretation of the data. AAIC Confidentiality Agreement Abstracts and related information submitted to the Alzheimer’s Association International Conference (AAIC®) meetings are considered final and confidential from the time of submission. This Confidentiality Agreement covers all abstracts, title of abstract and summary description placeholders ("Confidential Information"). Compliance with the Confidentiality Agreement is required by all parties receiving Confidential Information, which includes all embargoed or early copies of the abstracts shared with news media, as these documents are confidential per this policy and each recipient will be held accountable for any violations of AAIC’s Confidentiality Policy. Prior to the Confidential Information being publicly released by the Alzheimer’s Association in conjunction with the AAIC, authors, coauthors, sponsors of the research, news media, journalists, analysts, other AAIC attendees, and recipients of Confidential Information may not: Make the information public, or provide it to others who may make it public

Publish or present the information or provide it to others who may publish or present it

Use the information for any commercial purposes, pecuniary purposes, securities trading, securities recommendations and/or securities analysis until such information has been presented at AAIC and been reasonably absorbed on a broader basis into the market. For a study to be eligible for acceptance into the AAIC, information contained in the abstract, as well as additional data and information to be presented about the study at AAIC, must not be disclosed before the findings have been publicly released in conjunction with AAIC. Unless express permission is granted by the Alzheimer’s Association, which may be obtained directly upon request, the contents and conclusions of the abstract must not be presented at any scientific, medical or educational meeting or published in a scientific, medical or educational publication (in any medium) in whole or in part, before AAIC. If attendees wish to have information from an abstract or portions of the dataset disclosed in advance of public release in conjunction with AAIC, specific exception requests must be made per the Confidentiality Agreement Exception instructions described below. Alzheimer’s Association recognizes that certain federal and international laws require disclosure of certain clinical trial results through federal and international registries within a certain time period. If the imposed deadline for data submission falls before AAIC meeting dates, submission of the trial results to the required registry will not be viewed as a breach of AAIC’s Confidentiality Agreement. Confidentiality Agreement Exceptions Exceptions to the AAIC Confidentiality Agreement require communication with Alzheimer’s Association a minimum of 48 hours in advance of any public release. Specific inquiries about exceptions to the AAIC Confidentiality Agreement should be emailed to AAICConfidentiality@alz.org. A Securities and Exchange Commission (“SEC”) Exception is available to companies whose securities are publicly traded to the extent that disclosure is necessary for that company to comply with the disclosure requirements under any US federal or state or international securities laws. The obligations above shall not extend to any part of the Confidential Information (a) that can be demonstrated to have been in the public domain or publicly known at the time of disclosure; (b) that becomes part of the public domain or publicly known by publication or otherwise, not due to any unauthorized act by the abstract submitter; (c) that can be demonstrated as independently developed by the abstract submitter without reference to or reliance upon such Confidential Information; or (d) that is required to be disclosed by law, in which case the abstract submitter will notify the Alzheimer’s Association of such requirement. Other Exceptions to the AAIC Confidentiality Agreement may be granted by the Alzheimer’s Association in specific circumstances including but not limited to public health reasons and/or to meet the requirements of state, national or international government agencies. No matter if a Confidentiality Agreement Exception applies or is granted, Alzheimer’s Association retains the right, in its sole discretion, to change an abstract’s placement in the meeting program based on the extent of information disclosed. If an exception applies or is granted, the study will most likely be ineligible for the official AAIC news program. If the confidentiality policy is broken, the Alzheimer’s Association retains the right, in its sole discretion, to: remove the abstract from AAIC, deny the responsible author(s) attendance at AAIC, and/or bar the responsible author(s) from future submission and/or attendance at AAIC. News Embargo-Related FAQ's: Is advance promotion of general topics, speakers, or presentation times permitted? Public and news announcements made in advance of AAIC that a scientist or company is scheduled to make a presentation of AAIC may include the date, time, location and topic of presentation, but may not include the methods, results and/or the type or direction of results, even if that is included in the name/title of the submitted abstract. For that reason, authors are discouraged from putting the type and/or direction of results in the abstract title. Is it acceptable to submit an abstract that presents partial data from a manuscript submitted for publication? It is not acceptable to submit partial data from a manuscript already submitted for publication AND published in any form before the AAIC news embargo date/time. It is acceptable only if the author(s) and journal guarantee in writing to AAIC that any publication would not occur until after the AAIC news embargo date/time. Am I allowed to submit abstracts that have been previously presented? All abstracts submitted to AAIC must be made up substantially of new findings, data, or analyses. Will the submission of this abstract to affect the publication of our manuscript? No. These review processes are independent. The thresholds for acceptance between conference abstracts and journal manuscripts are very different. I have never attended a conference where the abstracts are published in an online supplement to a journal. Does this ever pose a problem for authors with subsequent publication of the research as a full article in a peer-reviewed journal, since the research findings would technically already have been published in Alzheimer's and Dementia: The Journal of the Alzheimer's Association? No. This does not pose a problem for authors. Academic literature has a clear distinction between conference abstracts and peer-reviewed papers. Frequently Asked Questions